Engineered protein scaffolds for molecular recognition

Journal of Molecular Recognition

Volumn 13, Issue 4, 2000, Pages 167-187

  Skerra, Arne ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Ligand binding; Molecular libraries; Polypeptide fold; Protein design; Structural framework

Indexed keywords

BINDING SITE; IMMUNOGLOBULIN; LIGAND BINDING; LIGAND; PROTEIN ENGINEERING; PROTEIN STRUCTURE; PROTEIN; RECEPTOR;

ANIMALS; CARRIER PROTEINS; HUMANS; IMMUNOGLOBULINS; PROTEASE INHIBITORS; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 0033865190     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9     Document Type: Review

References (115)

1. Al-Lazikani B, Lesk AM, Chothia C. 1997. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273: 927-948.
2. Altamirano MM, Blackburn JM, Aguayo C, Fersht AR. 2000. Directed evolution of new catalytic activity using the α/β-barrel scaffold. Nature 403: 617-322.
3. Beste G, Schmidt FS, Stibora T, Skerra A. 1999. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl Acad. Sci. USA 96: 1898-1903.
4. Bianchi E, Venturini S, Pessi A, Tramontano A, Sollazzo M. 1994. High level expression and rational mutagenesis of a designed protein, the minibody. J. Mol. Biol. 236: 649-659.
5. Bianchi E, Folgori A, Wallace A, Nicotra M, Acali S, Phalipon A, Barbato G, Bazzo R, Cortese R, Felici F, Pessi A. 1995. A conformationally homogeneous combinatorial peptide library. J. Mol. Biol. 247: 154-160
6. Bird RE, Walker BW. 1991. Single chain antibody variable regions. Trends Biotechnol. 9: 132-137.
7. Bishop RE, Penfold SS, Frost LS, Höltje J-V, Weiner JH. 1995. Stationary phase expression of a novel Escherichia coli outer membrane lipoprotein and its relationship with mammalian apolipoprotein D. J. Biol. Chem. 270: 23097-23103.
8. Blomberg N, Baraldi E, Nilges M, Saraste M. 1999. The PH superfold: a structural scaffold for multiple functions. Trends Biochem. Sci. 24: 441-445.
9. Bork P, Holm L, Sander C. 1994. The immunoglobulin fold -structural classification, sequence patterns and common core. J. Mol. Biol. 242: 309-320.
10. Braisted AC, Wells JA. 1996. Minimizing a binding domain from protein A. Proc. Natl Acad. Sci. USA 93: 5688-5692.
11. Brunet AP, Huang ES, Huffine ME, Loeb JE, Weltman RJ, Hecht MH. 1993. The role of turns in the structure of an α-helical protein. Nature 364: 355-358.
12. H antibody cloned from a fusion phage library of a vaccinated melanoma patient. Proc. Natl Acad. Sci. USA 93: 6280-6285.
13. Christmann A, Walter K, Wentzel A, Krätzner R, Kolmar H. 1999. The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Engng 12: 797-806.
14. Clackson T, Wells JA. 1994. In vitro selection from protein and peptide libraries. Trends Biotechnol. 12: 173-184.
15. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. 1996. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380: 548-550.
16. Cortese R, Monaci P, Nicosia A, Luzzage A, Felici F, Galfré G, Pessi A, Tramontano A, Sollazzo M. 1995. Indentification of biologically active peptides using random libraries displayed on phage. Curr. Opin. Biotechnol. 6: 73-80.
17. Cowan SW, Newcomer ME, Jones TA. 1990. Crystallographic refinement of human serum retinol-binding protein at 2 Å resolution. Proteins Struct. Funct. Genet. 8: 44-61.
18. Cull MG, Miller JF, Schatz PJ. 1992. Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac represser. Proc. Natl Acad. Sci. USA 89: 1865-1869.
19. Davies J, Riechmann L. 1995. Antibody VH domains as small recognition units. Bio/Technology 13: 475-479.
20. Davies J, Riechmann L. 1996. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Engng 9: 531-537.
21. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. 1999. A single-domain antibody fragment in complex with RNaseA: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7: 361-370.
22. DeGrado WF, Summa CM, Pavone V, Nastri F, Lombardi A. 1999. De novo design and structural characterization of proteins and metalloproteins. A. Rev. Biochem. 68: 779-819.
23. Dennis MS, Lazarus RA. 1994. Kunitz domain inhibitors of tissue factor-factor VIIa. J. Biol. Chem. 269: 22129-22136.
24. H antibody fragment in complex with lysozyme. Nature Struct. Biol. 3: 803-811.
25. Dimasi N, Matin F, Volpari C, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Steinkühler C, Sollazzo M. 1997. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol. 71: 7461-7469.
26. L domain confirms the structural model. J. Mol. Biol. 238: 226-244.
27. Fabbrizio E, Le Cham L, Polanowska J, Kaczorek M, Lamb N, Brent R, Sardet C. 1999. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 18: 4357-4363.
28. Flower DR. 1996. The lipocalin protein family: structure and function. Biochem. J. 318: 1-14.
29. Gachon A-MF, Lacazette E. 1998. Tear lipocalin and the eye's frontline of defense. Br. J. Ophthalmol. 82: 453-455.
30. Glockshuber R, Malia M, Pfitzinger I, Plückthun A. 1990. A comparison of strategies to stabilize immunoglobin Fv-fragments. Biochemistry 29: 1362-1367.
31. Glockshuber R, Schmidt T, Plückthun A. 1992. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro and functional expression in Escherichia coli. Biochemistry 31: 1270-1279.
32. Gunneriusson E, Nord K, Uhlén M, Nygren P-Å. 1999. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Engng 12: 873-878.
33. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Bajyana Songa E, Bendahman N, Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
34. 2+-binding protein. J. Am. Chem. Soc. 112: 6710-6711.
35. Hoess RH. 1993. Phage display of peptides and protein domains. Curr. Opin. Struct. Biol. 3: 572-579.
36. Hoogenboom HR. 1997. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15: 62-70.
37. Houshmand H, Froman G, Magnusson G. 1999. Use of bacteriophage T7 displayed peptides for determination of monoclonal antibody specificity and biosensor analysis of the binding reaction. Anal. Biochem. 268: 363-370.
38. Hurle MR, Gross M. 1994. Protein engineering techniques for antibody humanization. Curr. Opin. Biotechnol. 5: 428-433.
39. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246: 1275-1281.
40. Jung S, Honegger A, Plückthun A. 1999. Selection for improved protein stability by phage display. J. Mol. Biol. 294: 163-180.
41. Keck PC, Huston JS. 1996. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region. Biophys. J. 71: 2002-2011.
42. Koide A, Bailey CW, Huang X, Koide S. 1998. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284: 1141-1151.
43. Krizek BA, Amann BT, Kilfoil VJ, Merkle DL, Berg JM. 1991. A consensus zinc finger peptide: design, high-affinity metal binding, a pH-dependent structure, and a His to Cys sequence variant. J. Am. Chem. Soc. 113: 4518-4523.
44. Ku J, Schultz PG. 1995. Alternate protein frameworks for molecular recognition. Proc. Natl Acad. Sci. USA 92: 6552-6556.
45. Lamminmäki U, Paupério S, Westerlund-Karlsson A, Karvinen J, Virtanen PL, Lövgren T, Saviranta P. 1999. Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies. J. Mol. Biol. 291: 589-602.
46. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. 1993. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Bio/Technology 11: 187-194.
47. Le Nguyen DL, Heitz A, Chiche L, Castro B, Boigegrain RA, Favel A, Coletti-Previero MA. 1990. Molecular recognition between serine proteases and new bioactive microproteins with a knotted structure. Biochimie 72: 431-435.
48. Lerner RA, Benkovic SJ, Schultz PG. 1991. At the crossroads of chemistry and immunology: catalytic antibodies. Science 252: 659-667.
49. Li W, Liang S, Wang R, Lai L, Han Y. 1999. Exploring the conformational diversity of loops on conserved frameworks. Protein Engng 12: 1075-1086.
50. Lu Z, Murray KS, Van Cleave V, LaVallie ER, Stahl ML, McCoy JM. 1995. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Bio/Technology 13: 366-372.
51. Markland W, Ley AC, Lee SW, Ladner RC. 1996a. Iterative optimization of high-affinity protease inhibitors using phage display. 1. Plasmin. Biochemistry 35: 8045-8057.
52. Markland W, Ley AC, Ladner RC. 1996b. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35: 8058-8067.
53. Martin F, Toniatti C, Salvati AL, Venturini S, Ciliberto G, Cortese R, Sollazzo M. 1994. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. EMBO J. 13: 5303-5309.
54. Martin F, Toniatti C, Salvati AL, Ciliberto G, Cortese R, Sollazzo M. 1996. Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed β-protein IL-6 antagonist. J. Mol. Biol. 255: 86-97.
55. H domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Engng 10: 607-614.
56. Martin F, Steinkühler C, Brunetti M, Pessi A, Cortese R, De Francesco R, Sollazzo M. 1999. A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody. Protein Engng 12: 1005-1011.
57. Marshall GR. 1992. Three-dimensional structure of peptide-protein complexes: implications for recognition. Curr. Opin. Struct. Biol. 2:904-919.
58. Masat L, Wabl M, Johnson JP. 1994. A simpler sort of antibody. Proc. Natl Acad. Sci. USA 91: 893-896.
59. McConnell SJ, Hoess RH. 1995. Tendamistat as a scaffold for conformationally constrained phage peptide libraries. J. Mol. Biol. 250: 460-470.
60. Milne RW, Rassart E, Marcel YL. 1993. Molecular biology of apolipoprotein D. Curr. Opin. Lipidol. 4: 100-106.
61. Monaco HL, Rizzi M, Coda A. 1995. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268: 1039-1041.
62. Müller HN, Skerra A. 1994. Grafting of a high-affinity Zn(II)-binding site on the β-barrel of retinol-binding protein results in enhanced folding stability and enables simplified purification. Biochemistry 33: 14126-14135.
63. Muyldermans S, Lauwereys M. 1999. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J. Mol. Recogn. 12: 131-140.
64. H domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Engng 7: 1129-1135.
65. Nagi AD, Regan L. 1996. An inverse correlation between loop length and stability in a four-helix-bundle protein. Fold. Des. 2: 67-75.
66. Napolitano EW, Villar HO, Kauvar LM, Higgins DL, Roberts D, Mandac J, Lee SK, Engqvist-Goldstein A, Bukar R, Calio BL, Jack HM, Tainer JA. 1996. Glubodies: randomized libraries of glutathione transferase enzymes. Chem. Biol. 3: 359-367.
67. Newcomer ME, Jones TA, Åqvist J, Sundelin J, Eriksson U, Rask L, Peterson PA. 1984. The three-dimensional structure of retinol-binding protein. EMBO J. 3: 1451-1454.
68. Nixon AE, Firestine SM, Salinas FG, Benkovic SJ. 1999. Rational design of a scytalone dehydratase-like enzyme using a structurally homologous protein scaffold. Proc. Natl Acad. Sci. USA 96: 3568-3571.
69. Nord K, Nilsson J, Nilsson B, Uhlén M, Nygren P-Å. 1995. A combinatorial library of an α-helical bacterial receptor domain. Protein Engng 8: 601-608.
70. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlén M, Nygren P-Å. 1997. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nature Biotechnol. 15: 772-777.
71. Norman TC, Smith DL, Sorger PK, Drees BL, O'Rourke SM, Hughes TR, Roberts CJ, Friend SH, Fields S, Murray AW. 1999. Genetic selection of peptide inhibitors of biological pathways. Science 285: 591-595.
72. Nuttall SD, Rousch MJM, Irving RA, Hufton SE, Hoogenboom HR, Hudson PJ. 1999. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides. Proteins Struct. Funct. Genet. 36: 217-227.
73. Olivera BM, Rivier J, Clark C, Ramilo CA, Corpuz GP, Abogadie FC, Mena EE, Woodward SR, Hillyard DR, Cruz LJ. 1990. Diversity of Conus neuropeptides. Science 249: 257-263.
74. Padlan EA. 1994. Anatomy of the antibody molecule. Mol. Immunol. 31: 169-217.
75. Pessi A, Bianchi E, Crameri A, Venturini S, Tramontano A, Sollazzo M. 1993. A designed metal-binding protein with a novel fold. Nature 362: 367-369.
76. Predki PF, Agrawal V, Brünger AT, Regan L. 1996. Amino-acid substitutions in a surface turn modulate protein stability. Nature Struct. Biol. 3: 54-58.
77. Quéméneur E, Moutiez M, Charbonnier J-B, Ménez A. 1998. Engineering cyclophilin into a proline-specific endopepti-dase. Nature 391: 301-304.
78. Regan L, Clarke ND. 1990. A tetrahedral zinc(II)-binding site introduced into a designed protein. Biochemistry 29: 10878-10883.
79. Reiter Y, Brinkmann U, Lee B, Pastan I. 1996. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nature Biotechnol. 14: 1239-1245.
80. Reiter Y, Schuck P, Boyd LF, Plaksin D. 1999. An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J. Mol. Biol. 290: 685-698.
81. Riechmann L. 1996. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain. J. Mol. Biol. 259: 957-969.
82. Riechmann L, Muyldermans S. 1999. Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol. Meth. 231: 25-38.
83. Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature 332: 323-327.
84. Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, Ladner RC. 1992. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc. Natl Acad. Sci. USA 89: 2429-2433.
85. Roberts RW. 1999. Totally in vitro protein selection suing mRNA-protein fusions and ribosome display. Curr. Opin. Chem. Biol. 3: 268-273.
86. Röttgen P, Collins J. 1995. A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display. Gene 164: 243-250.
87. Schiweck W, Skerra A. 1995. Fermenter production of an artificial Fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins Struct. Funct. Genet. 23: 561-565.
88. ab fragment. J. Mol. Biol. 268: 934-951.
89. Schlehuber S, Beste G, Skerra A. 2000. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 297: 1105-1120.
90. Schmidt TGM, Skerra A. 1994. One-step affinity purification of bacterially produced proteins by means of the "Strep tag" and immobilized recombinant core streptavidin. J. Chromatogr. A 676: 337-345.
91. Schmidt AM, Müller HN, Skerra A. 1996. A Zn(II)-binding site engineered into retinol-binding protein exhibits metal-ion specificity and allows highly efficient affinity purification with a newly designed metal ligand. Chem. Biol. 3: 645-653.
92. Schultz PG, Lerner RA. 1995. From molecular diversity to catalysis: lessons from the immune system. Science 269: 1835-1842.
93. Shimizu T, Morikawa K. 1996. The β-prism: a new folding motif. Trends Biochem. Sci. 21: 3-6.
94. H domain: implications for antibody engineering. Protein Engng 5: 229-234.
95. Skerra A. 1993. Bacterial expression of immunoglobulin fragments. Curr. Opin. Immunol. 5: 256-262.
96. Skerra A, Plückthun A. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240: 1038-1041.
97. Smith GP. 1991. Surface presentation of protein epitopes using bacteriophage expression systems. Curr. Opin. Biotechnol. 2: 668-673.
98. Smith GP, Patel SU, Windass JD, Thornton JM, Winter G, Griffiths AD. 1998. Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage. J. Mol. Biol. 277: 317-332.
99. Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M. 1996. The crystal structure of a llama heavy chain variable domain. Nature Struct. Biol. 3: 752-757.
100. Steipe B, Plücktun A, Steinbacher S. 1994. Sequence statistics reliably predict stabilizing mutations in a protein domain. J. Mol. Biol. 240: 188-192.
101. Steipe B, Bruhn H, Funk M, Henkel T. 1997. Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces. International Patent Publication WO 97/45538.
102. Stevens FJ, Solomon A, Schiffer M. 1991. Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology. Biochemistry 30: 6803-6805.
103. Szardenings M, Vasel B, Hecht HJ, Collins J, Schomburg D. 1995. Highly effective protease inhibitors from variants of human pancreatic secretory trypsin inhibitor (hPSTI): an assessment of 3-D structure-based protein design. Protein Engng 8: 45-52.
104. Tanaka T, Urade Y, Kimura H, Eguchi N, Nishikawa A, Hayaishi O. 1997. Lipocalin-type prostaglandin D synthase (β-trace) is a newly recognized type of retinoid transporter. J. Biol. Chem. 272: 15789-15795.
105. Uhlén M, Forsberg G, Moks T, Hartmanis M, Nilsson B. 1992. Fusion proteins in biotechnology. Curr. Opin. Biotechnol. 3: 363-369.
106. Vita C. 1997. Engineering novel proteins by transfer of active sites to natural scaffolds. Curr. Opin. Biotechnol. 8: 429-434.
107. Vita C, Roumestand C, Toma F, Ménez A. 1995. Scorpion toxins as natural scaffolds for protein engineering. Proc. Natl Acad. Sci. USA 92: 6404-6408.
108. Vita C, Vizzavona J, Drakopoulou E, Zinn-Justin S, Gilquin B, Ménez A. 1998. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. Biopolymers 47: 93-100.
109. Wang CI, Yang Q, Craik CS. 1995. Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin. J. Biol. Chem. 270: 12250-12256.
110. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546.
111. Wells JA, Lowman HB. 1992. Rapid evolution of peptide and protein binding properties in vitro. Curr. Opin. Struct. Biol. 2: 597-604.
112. Widersten M, Mannervik B. 1995. Glutathione transferases with novel active sites isolated by phage display from a library of random mutants. J. Mol. Biol. 250: 115-122.
113. Woodward SR, Lourdes JC, Olivera BM, Hillyard DR. 1990. Constant and hypervariable regions in conotoxin propeptides. EMBO J. 9: 1015-1020.
114. Young KH. 1998. Yeast two-hybrid: so many interactions, in so little time. ... Biol. Reprod. 58: 302-311.
115. Zhao B, Helms LR, DesJarlais RL, Abdel-Meguid SS, Wetzel R. 1995. A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold. Nature Struct. Biol. 2: 1131-1137.